Ruxolitinib Cream

A topical cream formulation of the JAK inhibitor ruxolitinib was superior to its vehicle for treating vitiligo across all primary and secondary endpoints in two multicenter phase 3 trials presented together at the annual meeting of the European Academy of Dermatology and Venereology. On the primary endpoint of F-VASI 75 (75% improvement in the Facial
0 Comments